Investigating the effect of Cassia fistula extract on the improvement of ileus symptoms in patients with ileus after abdominal surgeries in 2025 - 2026

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250909067201N1

Enrollment

100

Registered

2025-09-26

Start date

2025-10-23

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ileus after abdominal surgery. Ileus, unspecified

Interventions

Intervention 1: Intervention group 1: 25 patients who were randomly selected by the REND method and underwent midline abdominal laparotomy. This group of patients took 500 mg of the extract in capsule

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with ileus after abdominal surgeries such as midline laparotomy and other procedures

Exclusion criteria

Exclusion criteria: Patients with multiple trauma Patients undergoing gastric sleeve surgery Patients with volvulus ??????? ????? ?? ??????????? History of infectious disease within the past 30 days Presence of comorbidity

Design outcomes

Primary

Measure	Time frame
Incidence and severity of ileus after abdominal surgery after taking capsules prepared from Cassia fistula extract. Timepoint: The severity of ileus will be monitored before the drug is administered and on days 1, 3, 7, 15, and 30 after the drug is administered. Also, its incidence will be monitored and followed up for 6 months after the onset of ileus. It should be noted that before the intervention begins and during the intervention period, on days 0 and 3 and every 3 months up to 6 months (2 periods), laboratory indicators (CBC/Diff, BUN, Creatinine, AST, ALT, ALP, Bili T&D, Albumin, PT, PTT, INR, U/A) will be monitored. Method of measurement: Age: Years, Gender: Male or female, Disease Duration: Time(days), Clinical Symptom Severity: ROME Criteria, CBC: Automated Cell Counter, AST, ALT, ALP, Bilirubin, Albumin, BUN, Creatinine: ELISA Kit, Urine Analysis: Dipstick, Apeearance and Microscopuic findings.	—

Measure

Time frame

Incidence and severity of ileus after abdominal surgery after taking capsules prepared from Cassia fistula extract. Timepoint: The severity of ileus will be monitored before the drug is administered and on days 1, 3, 7, 15, and 30 after the drug is administered. Also, its incidence will be monitored and followed up for 6 months after the onset of ileus. It should be noted that before the intervention begins and during the intervention period, on days 0 and 3 and every 3 months up to 6 months (2 periods), laboratory indicators (CBC/Diff, BUN, Creatinine, AST, ALT, ALP, Bili T&D, Albumin, PT, PTT, INR, U/A) will be monitored. Method of measurement: Age: Years, Gender: Male or female, Disease Duration: Time(days), Clinical Symptom Severity: ROME Criteria, CBC: Automated Cell Counter, AST, ALT, ALP, Bilirubin, Albumin, BUN, Creatinine: ELISA Kit, Urine Analysis: Dipstick, Apeearance and Microscopuic findings.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Hossein Salimi

Ilam University of Medical Sciences

salimi.a@medilam.ac.ir+98 84 3333 7861

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026